Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentivesBenzodiazepines and Related Sedatives
Peng L, Morford KL, Levander XA. Benzodiazepines and Related Sedatives. Medical Clinics Of North America 2022, 106: 113-129. PMID: 34823725, DOI: 10.1016/j.mcna.2021.08.012.ChaptersConceptsLong-term benzodiazepine useQuality of evidenceRisk of overdoseSignificant adverse effectsCognitive behavioral therapySedative useBenzodiazepine useBenzodiazepine discontinuationPharmacologic propertiesBenzodiazepine taperWithdrawal managementPhysical dependenceBehavioral treatmentBehavioral therapyBenzodiazepinesDetoxification facilityNovel psychoactive substancesAdverse effectsDesigner benzodiazepinesPsychoactive substancesMost benefitDiscontinuationMedicationsSedativesOverdose